Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
RUA Life Sciences makes progress with heart valve leaflet composite
(Sharecast News) - RUA Life Sciences updated the market on its progress with the RUA leaflet composite on Wednesday. The AIM-traded firm said its RUA Structural Heart division was on a mission to evaluate heart valve leaflet materials and compare the performance of 100% polymeric valves with their novel composite material.
Computational modelling at the design stage indicated that the mechanical properties of the composite would be well-suited for heart valve leaflets.
RUA said it conducted rigorous testing, with the composite showing remarkable flex fatigue stability, enduring over 400 million cycles.
The composite displayed impressive durability as a heart valve leaflet, withstanding over 200 million cycles.
It exhibited exceptional tensile strength properties, surpassing base fabric and polymer materials, and demonstrated consistent tensile strength in multiple directions.
The board said the material's high flexibility enhanced valve efficiency, while its narrow crimping profile offered advantages in transcatheter aortic valve replacement (TAVR) procedures.
Moreover, it retained important blood-contacting properties, such as resistance to calcification and thrombogenicity.
The material remained stable throughout testing, with no delamination observed, demonstrating high tear resistance.
Following the test results, RUA said it had started seeking patent protection for the composite material.
At the same time, the company said it was actively pursuing opportunities to commercialise the RUA composite as a viable alternative to animal tissue currently used in heart valve manufacturing.
The board said the industry's response to the innovative material was positive, with RUA previously announcing that a significant heart valve company had expressed interest.
That company had entered into a material testing agreement with RUA to evaluate the composite's potential further.
"Combining RUA's expertise in implantable textile materials with the clinically proven properties of ElastEon has created a novel material that appears to meet the key properties required of heart valve leaflets and it is pleasing that the business is now transitioning from a research and development phase into early stages of commercialisation," said chairman Bill Brown.
At 1205 GMT, shares in RUA Life Sciences were down 2.39% at 10.01p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
